Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications - PubMed (original) (raw)

Review

. 2015 Mar 2;4(4):e1008814.

doi: 10.1080/2162402X.2015.1008814. eCollection 2015 Apr.

Norma Bloy 2, Fernando Aranda 3, Francesca Castoldi 4, Alexander Eggermont 5, Isabelle Cremer 6, Wolf Hervé Fridman 7, Jitka Fucikova 8, Jérôme Galon 9, Aurélien Marabelle 10, Radek Spisek 11, Eric Tartour 12, Laurence Zitvogel 10, Guido Kroemer 13, Lorenzo Galluzzi 14

Affiliations

Review

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Aitziber Buqué et al. Oncoimmunology. 2015.

Abstract

Immunomodulatory monoclonal antibodies (mAbs) differ from their tumor-targeting counterparts because they exert therapeutic effects by directly interacting with soluble or (most often) cellular components of the immune system. Besides holding promise for the treatment of autoimmune and inflammatory disorders, immunomodulatory mAbs have recently been shown to constitute a potent therapeutic weapon against neoplastic conditions. One class of immunomodulatory mAbs operates by inhibiting safeguard systems that are frequently harnessed by cancer cells to establish immunological tolerance, the so-called "immune checkpoints." No less than 3 checkpoint-blocking mAbs have been approved worldwide for use in oncological indications, 2 of which during the past 12 months. These molecules not only mediate single-agent clinical activity in patients affected by specific neoplasms, but also significantly boost the efficacy of several anticancer chemo-, radio- or immunotherapies. Here, we summarize recent advances in the development of checkpoint-blocking mAbs, as well as of immunomodulatory mAbs with distinct mechanisms of action.

Keywords: CRC, colorectal carcinoma; CTLA4, cytotoxic T lymphocyte-associated protein 4; FDA, Food and Drug Administration; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; MEDI4736; MPDL3280A; NK, natural killer; NSCLC, non-small cell lung carcinoma; PD-1, programmed cell death 1; RCC, renal cell carcinoma; TGFβ1, transforming growth factor β1; TLR, Toll-like receptor; TNFRSF, tumor necrosis factor receptor superfamily; Treg, regulatory T cell; ipilimumab; mAb, monoclonal antibody; nivolumab; pembrolizumab; urelumab.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, et-al.. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383–95; PMID:; http://dx.doi.org/10.1056/NEJMoa0904492 - DOI - PubMed
    1. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et-al.. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343:1594–602; PMID:; http://dx.doi.org/10.1056/NEJM200011303432202 - DOI - PubMed
    1. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA.. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997–1008; PMID:; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214 - DOI - PubMed
    1. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L.. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7:95-106; PMID:; http://dx.doi.org/10.1038/nrc2051 - DOI - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:; http://dx.doi.org/10.1038/nrc3239 - DOI - PMC - PubMed

Publication types

LinkOut - more resources